DASATINIB FOR USE IN THE TREATMENT, REGRESSION OR DECELERATING THE PROGRESS OF FIBROTIC LUNG DISEASES

摘要

The present invention relates to the use of dasatinib or its pharmaceutically acceptable salts thereof as a potential pharmaceutical agent, more preferably anti-proliferative or anti-fibrotic agent in fibrotic lung diseases, in particular idiopathic pulmoner fibrosis (IPF) disease.